Analysts pointed out that the recent GEM index has repeatedly hit new highs. On the one hand, the trend of the GEM's 2019 performance forecast has provided a rising background. On the other hand, the high technology content also adds another layer of rising background to the GEM, that is, the double background of performance + technology. At present, under the background of state-led high-tech innovation strategieBuy Singapore stockss, the main line market of ChiNext is still worth looking forward to.
In terms of sectors, the One Belt One Road concept is still the focus of capital attention. The transportation facilities sector has performed more prominently. Port stocks such as Lianyungang, Nanjing Port and Rizhao Port have their daily limit. The Silk Road, transportation services and other sectors ranked among the top gainers. Regional hotspots continue to develop in depth, and it is the turn of the Shaanxi plate. Sub-new stocks have become the hardest hit areas for intraday drops today, with 44 companies experiencing a drop of more than 8%. Sub-new stocks have continued to rise in the past two months, and there are many profitable shares, and the stock prices of many sub-new stocks have deviated from the basic value by a large margin. As long as the market wind changes, under the dual pressure of profit-making exit and value return, The volatility will be significantly larger than other sectors.
Judging from the current situation of the A-share market, listed companies are mostly manufacturing and R&D companies with certain strengths in various industries or with certain brands. The financing activities during the IPO process play an important role in helping companies grow and promote the development of the real economy. .
On the 13th, the European Commission announced that it has completed tentative negotiations to pre-order 200 million doses of the new coronavirus vaccine under development from Johnson & Johnson in the United States. The agreement also includes the EU's right to first purchase another 200 million doses of Johnson & Johnson vaccine. In addition, the European Union and AstraZeneca signed a purchase agreement to purchase at least 300 million new crown vaccines, and another 100 million can be optionally purchased. The European Union announced in July that it has completed preliminary negotiations with the French Sanofi Group to purchase 300 million doses of the new crown vaccine that Sanofi and GlaxoSmithKline are co-developing. The EU stated that the EU is also negotiating pre-purchase agreements with Pfizer Pharmaceuticals, Modena, and German Cure Vaccines.
In the first half of 2019, ArcherMind achieved operating income of 9.3 billion yuan, a year-on-year increase of 247%, and net profit attributable to shareholders of listed companies was 8.99 million yuan, a year-on-year decrease of 491%; after deducting non-recurring gains and losses attributable to shareholders of listed companies The net profit was a loss of 2.5095 million yuan; the net cash flow from operating activities was -216.6 million yuan.
From the drop contribution list, it can be seen that Kangtai Bio, Aier Ophthalmology, Zhifei Biology, and Watson Biology occupy the top four respectively, constituting an 11-point drop in the index, and pharmaceutical stocks occupy 9 seats in the top 15 drop-contributing lists. 60%, it can be said that it is the weakness of today's pharmaceutical stocks that led to the 6 consecutive Buy Singapore stocksnegatives on the GEM.